Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor
Christiani, K.; Möller, W.D.
Münchener Medizinische Wochenschrift 115(16): 711-713
1973
ISSN/ISBN: 0341-3098 PMID: 4197758 Document Number: 65730
Document emailed within 1 workday
Related Documents
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Fischer, P.A.; Schneider, E.; Jacobi, P.; Maxion, H. 1973: Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor Die Medizinische Welt 24(45): 1742-1746
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Eisenlohr, J.J.; Gehlen, W. 1974: Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) Münchener Medizinische Wochenschrift 116(28): 1353-1356
Eisenlohr, J.J.; Gehlen, W. 1975: Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor) Der Nervenarzt 46(3): 128-135
Rabadeau Dumas, J.L.; Rondot, P.; Cardon, P. 1977: Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor Therapie 32(2): 161-172
Pontiroli, A.E.; Castegnaro, E.; Vettaro, M.P.; Viberti, G.C.; Pozza, G. 1977: Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine Acta Endocrinologica 84(1): 36-44
Geissbuhler, F.; Eisenring, J.J.; Friedli, P.; Bartholini, G.; Tissot, R. 1972: Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects L'Encephale 61(2): 127-148
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Stammler, A.; Vielhaber, K. 1972: Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor Fortschritte der Neurologie Psychiatrie und Ihrer Grenzgebiete 40(10): 564-568
Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Zabel, M. 1979: Ultrastructure of thyroid C cells following long-term administration of 1-DOPA or alpha-methyl-DOPA Acta Medica Polona 20(1): 53-54
Wajsbort, J.; Hemli, J.A.; Alfandary, I.; Yahel, M.; Siegfried, J. 1971: Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association Wiener Medizinische Wochenschrift 121(42): 741-745
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215
Clough, C.G.; Bergmann, K.J.; Yahr, M.D. 1984: Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration Advances in Neurology 40: 131-140
Matussek, N.; Benkert, O.; Schneider, K.; Otten, H.; Pohlmeier, H. 1970: Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions Arzneimittel-Forschung 20(7): 934-935
De Divitiis, E.; Cerillo, A.; Tata, M.R.; Decina, A. 1973: Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results Acta Neurologica 28(2): 208-212